Breast cancer vaccine - Therion Biologics
Alternative Names: Breast cancer vaccine NY-ESO-1 - Therion Biologics; CEA vaccine - Therion; HER-2/neu vaccine - Therion; MUC-1 vaccine - Therion; TBC NEULatest Information Update: 25 Sep 2021
At a glance
- Originator Therion Biologics
- Developer National Cancer Institute (USA); Therion Biologics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 25 Jun 2001 Phase-I clinical trials for Breast cancer in USA (Injection)
- 29 Aug 1996 Preclinical development for Breast cancer in USA (Injection)